2017 Fair Pricing Forum: The Message for Pharma CEOs

Posted by Ed Schoonveld on Tue, Jul 18, 2017

This article was originally published in the June 2017 issue of In Vivo.

Drug pricing continues to be a social and political dilemma that forms a divide between the drug industry on one side and medical community, governments and patients on the other side. Frustrations over the high cost of prescription drugs have resulted in a groundswell of government and private initiatives to increase transparency, analyze value through various frameworks or directly control pricing.


>
Read More

US Drug Pricing: Pushing Beyond Soundbites to Offer Real Solutions

Posted by Ed Schoonveld on Wed, Mar 15, 2017

Drug pricing is a recurring topic amongst U.S. politicians and the media, and it experiences the occasional erratic peak in attention when President Trump aims his early morning tweets at pharma. It’s a much more complex topic than can be discussed in 140 characters, however, and unfortunately, the pharmaceutical industry thus far hasn’t been able to provide compelling answers to politicians and the public. Some bad actors, such as Turings’s ex-CEO Martin Shkreli, have seriously harmed the industry’s reputation, and pharmaceutical companies now need to act.


>
Read More

Paper on Drug Costs From American College of Physicians Ignores Economic Reality

Posted by Ed Schoonveld on Wed, Apr 06, 2016

Providing a view of the issue of rising drug costs, plus specific positions and recommendations for government action, the American College of Physicians (ACP) published a position paper on March 29, 2016, titled “Stemming the Escalating Cost of Prescription Drugs: A Position Paper of the College of the American College of Physicians.”


>
Read More

Re-Pricing Rules in Japan Slash Prices for “Huge Sales” Drugs

Posted by Ed Schoonveld on Mon, Feb 01, 2016

At a recent meeting of the Japanese Central Social Insurance Medical Council (Chuikyo), substantial price cuts for drugs with “huge sales” were discussed. These cuts are to be implemented in April and will impact four brands:


>
Read More

Clinton on Drug-Pricing Warpath: Populism, Real Problem or Both?

Posted by Ed Schoonveld on Mon, Jan 11, 2016

When pointing a finger at someone, usually three fingers are pointed at yourself. U.S. government and presidential candidates should consider this before they rush to the media briefing rooms.


>
Read More